Analysis of the anti-fibrotic potential of a JAK inhibitor in a bleomycin-induced pulmonary fibrosis model
Our data suggest that baricitinib may improve pulmonary fibrosis by directly inhibiting fibroblast activation via JAK2 blockade. J. Med. Invest. 72 : 298-307, August, 2025.
Authors
- Hirohisa Ogawa (ORCID: https://orcid.org/0000-0002-6750-5439)
- Keiko Haji
- Nobuhito Naito (ORCID: https://orcid.org/0000-0001-8748-7648)
- Yuya Yamashita (ORCID: https://orcid.org/0000-0003-2540-0521)
- Takeshi Imakura
- Hiroki Bando
- Seidai Sato (ORCID: https://orcid.org/0000-0001-7052-764X)
- Hiroshi Kawano (ORCID: https://orcid.org/0000-0001-9812-4615)
- Kazuya Koyama (ORCID: https://orcid.org/0000-0001-6946-9462)
- Yoshihiro Nishimura (ORCID: https://orcid.org/0000-0002-0168-8746)
- Kojin Murakami
- Haruka Nishimura
- Yuta Isomura
- Kozo Kagawa
- Yasuhiko Nishioka
Institutions
- Center for Rheumatology (US)
- Kobe University (JP)
- Tokushima University (JP)
Publication Details
- Journal
- The Journal of Medical Investigation
- Published
- 2025-01-01
- DOI
- https://doi.org/10.2152/jmi.72.298
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science